Cargando…

Rituximab Therapy for Adults with Nephrotic Syndromes: Standard Schedules or B Cell-Targeted Therapy?

Rituximab is a chimeric anti-CD20 monoclonal antibody. It acts mainly through complement-dependent cytotoxicity on B cells expressing the CD20 marker. In this review, we analyse the efficacy and possible pitfalls of rituximab to treat nephrotic syndromes by taking into account pharmacological consid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Del Vecchio, Lucia, Allinovi, Marco, Rocco, Paolo, Brando, Bruno
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8709396/ https://www.ncbi.nlm.nih.gov/pubmed/34945143 http://dx.doi.org/10.3390/jcm10245847

Ejemplares similares

Rituximab therapy in adults with steroid-dependent nephrotic syndrome
por: Zhong, Hongzhen, et al.
Publicado: (2019)

Rituximab for nephrotic syndrome in children
por: Iijima, Kazumoto, et al.
Publicado: (2016)

Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome
por: Counsilman, Clare E., et al.
Publicado: (2015)

Rituximab Treatment for Nephrotic Syndrome in Children
por: Iijima, Kazumoto, et al.
Publicado: (2014)

Effectiveness of rituximab in nephrotic syndrome treatment
por: Popko, Katarzyna, et al.
Publicado: (2017)

Circulating Anti-Rituximab Antibodies Do Not Affect Response to Rituximab in Steroid-Dependent Nephrotic Syndrome
por: Angeletti, Andrea, et al.
Publicado: (2022)

Rituximab Use in the Management of Childhood Nephrotic Syndrome
por: Kallash, Mahmoud, et al.
Publicado: (2019)

Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome
por: Fenoglio, Roberta, et al.
Publicado: (2018)

Successful Treatment of New-Onset Pediatric Nephrotic Syndrome With Rituximab as a First-Line Therapy
por: Zhang, Xiaojing, et al.
Publicado: (2022)

Rituximab therapy for childhood onset idiopathic nephrotic syndrome: experience of a Portuguese tertiary center
por: Gomes, Rita, et al.
Publicado: (2022)

Difficulties in diagnosing severe Pneumocystis jiroveci pneumonia after rituximab therapy for steroid-dependent nephrotic syndrome
por: Czarniak, Piotr, et al.
Publicado: (2013)

Rituximab in idiopathic nephrotic syndrome: still waiting for stronger evidences
por: Belangero, Vera Maria Santoro
Publicado: (2023)

Successful Pregnancies in a Patient with Childhood-onset Steroid-dependent Nephrotic Syndrome during Rituximab Maintenance Therapy
por: Nara, Mizuho, et al.
Publicado: (2021)

Efficacy of rituximab therapy in children with nephrotic syndrome: a 10-year experience from an Iranian pediatric hospital
por: Bazargani, Behnaz, et al.
Publicado: (2022)

Rituximab is not a “magic drug” in post-transplant recurrence of nephrotic syndrome
por: Grenda, Ryszard, et al.
Publicado: (2016)

Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials
por: Iijima, Kazumoto, et al.
Publicado: (2017)

The efficacy and safety of rituximab in treating childhood nephrotic syndrome: an Italian perspective
por: Maratea, Dario, et al.
Publicado: (2016)

A prospective cohort study of rituximab in the treatment of refractory nephrotic syndrome
por: Xu, Jing, et al.
Publicado: (2021)

Hypokalemia after rituximab administration in nephrotic syndrome: two case reports
por: Song, Yiyun, et al.
Publicado: (2023)

Cost-Effectiveness of Administering Rituximab for Steroid-Dependent Nephrotic Syndrome and Frequently Relapsing Nephrotic Syndrome: A Preliminary Study in Japan
por: Takura, Tomoyuki, et al.
Publicado: (2017)

Nephrotic Syndrome: Genetics, Mechanism, and Therapies
por: Shin, Jae Il, et al.
Publicado: (2018)

Extracorporeal Therapy for Idiopathic Nephrotic Syndrome
por: Au, Eric, et al.
Publicado: (2021)

Zinc supplementation as an adjunct to standard therapy in childhood nephrotic syndrome - a systematic review
por: Bhatt, Girish Chandra, et al.
Publicado: (2016)

PD42 - Is rituximab a trigger for persistent hypogammaglobulinemia in idiopathic nephrotic syndrome?
por: Trujillo, Juan Enrique, et al.
Publicado: (2014)

Kinetics of Rituximab Excretion into Urine and Peritoneal Fluid in Two Patients with Nephrotic Syndrome
por: Stahl, Klaus, et al.
Publicado: (2017)

Late-Onset Neutropenia after Rituximab Treatment for Adult-Onset Nephrotic Syndrome
por: Yamazaki, Mayuko, et al.
Publicado: (2019)

Long-term repeated rituximab treatment for childhood steroid-dependent nephrotic syndrome
por: Kim, Ji Hyun, et al.
Publicado: (2017)

Rituximab experience in children with nephrotic syndrome: what have we observed differently
por: Girişgen, İlknur, et al.
Publicado: (2020)

Early Use of Rituximab in Calcineurin Inhibitor–Refractory and Steroid-Resistant Nephrotic Syndrome
por: Sinha, Rajiv, et al.
Publicado: (2020)

Children with Steroid Dependent Nephrotic Syndrome: Rituximab or Tacrolimus? It’s All in the Timing
por: Qader, Md Abdul, et al.
Publicado: (2023)

Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey
por: Zurowska, Aleksandra, et al.
Publicado: (2023)

Rituximab treatment for refractory nephrotic syndrome in adults: a multicenter retrospective study
por: Ma, Xiaoyan, et al.
Publicado: (2023)

Targeted Therapy with Rituximab in Felty’s Syndrome: A Case Report
por: Heylen, Line, et al.
Publicado: (2012)

The Nephrotic Syndrome in Childhood: Prolonged Glucocorticoid Therapy
por: Gryboski, Joyce D., et al.
Publicado: (1962)

Nephrotic Syndrome and Statin Therapy: An Outcome Analysis
por: Busuioc, Ruxandra, et al.
Publicado: (2023)

Efficacy of Semiannual Single Fixed Low-Dose Rituximab Therapy in Steroid-Dependent Minimal Change Nephrotic Syndrome: A Case Series
por: Usui, Ryosuke, et al.
Publicado: (2018)

The efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome: A meta-analysis
por: Zhao, Zhihong, et al.
Publicado: (2015)

Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome
por: Maxted, Andrew P., et al.
Publicado: (2018)

Rituximab for Children With Difficult-to-Treat Nephrotic Syndrome: Its Effects on Disease Progression and Growth
por: Topaloğlu, Rezan, et al.
Publicado: (2019)

Hypokalemia After Rituximab Administration in Steroid-Dependent Nephrotic Syndrome: A Case Report
por: Guzzi, Francesco, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gv0ploush7c5iv2vfufnm53315